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Introduction
The phosphatidylinositol 3-kinase (PI3K) pathway is a key signalling pathway in cancer. mTOR is a serine/threonine kinase acting as a sensor of mitogen, energy and nutrient levels and a central controller of cell growth downstream of PI3K (Laplante and Sabatini, 2012) . Many therapeutic strategies are currently in development to inhibit the PI3K/mTOR signalling pathway (Chiarini et al., 2015) . Allosteric inhibitors of mTOR such as rapamycin have clinical activity but reactivate PI3K signalling due to feedback (O'Reilly et al., 2006) . In patients with PTEN-negative glioma, this impaired the clinical activity of rapamycin (Cloughesy et al., 2008) . AZD8055 is a potent and selective inhibitor of mTOR kinase (Chresta et al., 2010 Garcia-Martinez and Alessi, 2008) . Chronic administration of AZD8055 induces a broad antitumour effect in xenograft models across different human tumour types, but it is mostly cytostatic (Chresta et al., 2010) . Several pharmacokinetic (PK)/pharmacodynamic (PD) and efficacy models have been developed for allosteric mTOR inhibitors such as everolimus or more recently PI3K and PI3K/mTOR kinase inhibitors (Tanaka et al., 2008; Salphati et al., 2010 Salphati et al., , 2012 . For everolimus, a PK/PD relationship between biomarker data obtained from surrogate tissues and antitumour efficacy suggested that human drug exposure was comparable with that observed in preclinical models at efficacious doses (Tanaka et al., 2008) . More recently, a PK/PD model using biomarker modulation in tumours with a pan-PI3K inhibitor GDC-0941 established a threshold of chronic biomarker modulation to drive tumour stasis (Salphati et al., 2010) . A similar study with the mixed PI3K/mTOR inhibitor GDC-0980 proposed a predicted dose for human efficacy by substituting the preclinical PK parameters for the human PK parameters (Salphati et al., 2012) . None of these reports models the relationship between PK, PD and efficacy across a range of xenografted tumour models.
Dose and schedule can significantly affect the antitumour effect of targeted agents, and Solit et al. (2005) previously demonstrated that pulsatile dosing at high doses with gefitinib could modulate the biological mechanism of action from growth inhibition to cell death in models unresponsive to gefitinib. Phase 1 studies with agents targeting the PI3K and mTOR pathways have tested different dose and schedules to mitigate some of the adverse events associated with these agents. However, there is limited information on the rational alteration of dose and schedules based on PK/PD/efficacy modelling.
The current study reports the development of a PK/PD model with AZD8055 across a number of preclinical models with differential antitumour effects. This mathematical modelling approach tests the hypothesis that there is a quantitative relationship between drug exposure, using plasma as a surrogate for tissue exposure, the observed response on pathway biomarkers in tumours and the resulting tumour growth inhibition. It also tests the concept of high-dose intermittent dosing, its impact of PK/PD modelling and limitations for clinical studies.
Methods

Cell culture
All cell lines were cultured in RPMI 1640 + 10% fetal calf serum +1% glutamine. All cells were obtained from the American Type Culture Collection.
Immunoblotting
Tumour tissue lysates were prepared as previously described (Holt et al., 2012) . Briefly, protein lysates were prepared from frozen tumours using the FastPrep-24 (MP Biomedicals, Solon, OH, USA) in 10 × lysis buffer (Cell Signalling Technology, Danvers, MA, USA) diluted to 1 × in PBS containing phosphatase inhibitor cocktails I and II (Sigma, St Louis, MO, USA) and protease inhibitor cocktail (Sigma). Protein concentration was determined by BCA assay (Pierce, Cramlington, UK 
Immunohistochemistry
Ki67 nuclear staining was carried out using formalin-fixed, paraffin-embedded xenografts tissue sections. Ki67 immunohistochemical nuclear staining was scored using an algorithm developed for scoring percentage positive nuclei on an ACIS II image analyser (ChromaVision Medical Systems, Inc.) using standard threshold settings.
In vivo efficacy studies
All animal care and experimental procedures complied with institutional guidelines and all current regulations and standards of the Home Office UK and were approved under UK Home Office Project Licence 30/2934. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath & Lilley, 2015) . Specific, pathogen-free, female mice (nu/nu: Alpk) were bred in house. They were housed and maintained in specific, pathogen-free conditions. The mice were used between the ages of 8 and 12 weeks in accordance with, and all procedures were carried out Human tumour xenografts were established by s.c. injection into the left-hand flank of 1-5 × 10 6 cells depending of the models in a final volume of 0.1 mL. When the mean tumour volume reached~0.2 cm 3 , the mice were randomized into vehicle (n = 12-14) or AZD8055-treated groups (n = 8-12). Tumour volumes (measured by calliper), animal body weight and tumour condition were recorded twice weekly for the duration of the study. Tumour volume was calculated as (length × width) × √(length × width) × (π/6) (Tomayko and Reynolds, 1989) . Growth inhibition from the start of treatment was assessed by comparison of the differences in tumour volume between control and treated groups. Because the variance in mean tumour volume data increases proportionally with volume (and is therefore disproportionate between groups), data were log-transformed to remove any size dependency before statistical evaluation. Statistical significance was evaluated using a onetailed, two-sample t-test. Mice were killed by CO 2 euthanasia.
Pharmacokinetic/pharmacodynamic studies Animals were randomized (n = 3-9 per group) when tumours reached an average of 0.7 cm 3 and were humanely killed and samples collected at indicated time-points following drug administration. Tumour tissue was cut into two pieces; one half was snap frozen in liquid nitrogen and transferred to À80°C for PD analysis (using immunoblotting or mesoscale), whereas the other was fixed in 10% formalin buffer for 24 h and embedded in paraffin for immunohistochemical staining. Total blood was collected by intracardiac puncture, and plasma was prepared and immediately frozen at À20°C for PK analysis. Plasma samples were extracted by online solid phase extraction and analysed by HPLC/MS using a reversed-phase SunFire C18 RP column (Waters) and a gradient mobile phase containing water : acetonitrile : formic acid. Peaks were detected using an AB Sciex API5000. The assay had a range of 0.3-50 ng·mL À1 .
PK/PD modelling
All modelling was performed in ACSLX v 2.5(Aegis Technologies, 410 Jan Davis Drive, Huntsville, AL 35806). Models as described below were defined as differential equations and solved numerically. Parameter estimates were obtained using nonlinear least-squares regression: the model predictions were compared with the observed data using the sum of the square difference between the model and the data, this value being minimized by varying the model parameter values. For the PK data, it was assumed that the measurement noise was proportional to the signal to account for the several orders of magnitude displayed in the data and so residuals were weighted by the model prediction. Supporting Information- Figure S2 demonstrates the variation of the data about the model prediction is uniform on a log-scale confirming this assumption. For the PD and tumour volume data, it was assumed that measurement error was constant and so unweighted residuals were used. Again, the diagnostic plots shown in Supporting Information Figures S3, S4 and S5 show that the variation of the data around the model prediction is uniform.
The model is composed of three modules, a linear compartmental PK model, indirect response models representing the effects on pAkt Ser 473 and pS6 Ser 240/244 and then an adaptation of the model reported by Simeoni et al. (2004) . The model makes a number of assumptions that are then validated against the data:
1. The PK is linear. 2. Plasma concentration may be used as a surrogate for tissue exposure. 3. Inhibition of biomarker is directly correlated with tumour growth inhibition. That is, if the biomarkers are reduced by 50% of control, then the tumour will grow at 50% of the control rate at that point in time.
Pharmacokinetic model
Measured plasma levels of drug after dosing in the pharmacology studies were supplemented by richly sampled lowdose oral and intravenous data obtained in discrete PK studies. After some model development, a linear two-compartment model with two rates of absorption for oral doses was chosen ( Figure 1) .
where predicted plasma concentration of AZD8055 is described by the following:
Here, CEN is the central compartment identified with blood, and PER is the peripheral compartment often identified with tissue. The model therefore characterizes the clearance, CL and volume of distribution, V1 + V2, when PK data
Figure 1
Diagram of the mathematical PKPD and efficacy model. The model is arranged into three distinct modules. The first is the PK model, and the second links the modelled plasma drug concentration to the effects of the drug on the biomarkers. The third module is a model of xenograft growth over time. Drug effect was linked to xenograft growth via the biomarkers.
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from iv dosing are included in the analysis (as they are here). It also characterizes the bioavailability and rate of oral absorption in the mouse: GUT FAST represents rapid absorption with rate ka FAST and GUT SLOW represents slower absorption with rate ka SLOW . A parameter frac defines the fraction of the dose that is absorbed at the fast rate. The model can be calibrated against existing PK data and used to simulate PKs for experiments where PK data could not be derived.
Pharmacodynamic model
Mechanistically, inhibition of the mTOR kinase will result in a reduction in the phosphorylation of the two downstream biomarkers, pAkt Ser 473 and pS6 Ser 240/244 . This is represented mathematically by an indirect response model with inhibition of phosphorylation (Figure 1) . The model form is the same for the two biomarkers, and so, the generic form of the type I (Dayneka et al., 1993) indirect response model is shown for biomarker response R dR dt
Here, R 0 is the baseline phosphorylated level, I max is the maximum level of inhibition achievable, IC 50 is the concentration required to achieve 50% of the maximal inhibition and kout described the rate of decay of the response. In the situation considered here, kout can be considered to be the rate of de-phosphorylation.
Similar to the PK model, the PD model can be calibrated against existing data and used to simulate PD for experiments where data could not be derived.
Xenograft growth model
The study used a modified descriptive 'Simeoni' model of Xenograft, with or without drug treatment as described by Rocchetti et al. (2005) . Tumour volume is predicted as the sum of the four states.
In the mathematical model of tumour growth, there are two compartments representing cells progressing through the cell cycle (Cycling) and cells in phase G0 (NonCycling). The rate that cells enter the cycling state becomes more limited as the tumour increases in volume, as characterized by the switching parameter ϕ and shows the same exponential to linear growth behaviour as the model from which it was adapted. To simulate cell growth, for a given cell volume leaving the cycling compartment, twice the volume arrived in the NonCycling compartment to represent mitosis. In the model equations, λ 0 is the exponential rate of growth and λ 1 is the linear growth rate for larger tumour sizes, similar to the Simeoni model. The model was modified to test whether the antitumour effect could be predicted based on the extent and duration of the PD effects: Inhibition of growth (proliferation), Inhib, was a function of the relative inhibition of the two biomarkers; inhibition of cells progressing through the cell cycle was modelled by passage of cells from the Cycling to the NonCycling compartment (and the consequent cell doubling) being reduced proportional to the biomarker inhibition. Importantly, it is assumed that at 100% biomarker inhibition, the tumour stopped growing. The parameter P represented the relative importance of the two biomarkers for predicting tumour growth. Here, AKT 0 and S6 0 are the baseline PD parameters.
This model only predicts a cytostatic effect as a maximum. To reflect regressions seen in some cases, an additional cell death effect was added as the third term of the Cycling differential equation. E max is the maximum rate of cell kill attainable. MRT is the average residence time of cells in the Cycling state, and MRT50 is the value the MRT has to be extended to (due to reduction in proliferation) for cell death to occur in the model. The parameter N defines the steepness of this relationship between proliferation reduction and cell kill. Thus, this effect characterizes the relationship between cell cycle inhibition and cell death.
There are two additional compartments (DEAD 1 and DEAD 2 ) that represent cells that have been killed but still form part of the tumour mass. These compartments provided a delay between cell kill and the reduction in tumour volume, characterized by the parameter K1 (Table 1) . Two delay compartments were found to be sufficient.
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . For in vivo studies, data were logtransformed to remove any size dependency before statistical evaluation. Statistical significance was evaluated using a onetailed, two-sample t-test.
Materials
AZD8055 was synthesized by AstraZeneca Inc (Alderley Park, UK). Purity was >97%. For administration by oral gavage, AZD8055 was solubilized in 30% (w/v) Captisol, pH 5.0. For i.p. administration, AZD8055 was dissolved in water for injection. All other chemicals were from Sigma Aldrich (St Louis, MO, USA) unless specified.
Results
Pharmacokinetic/pharmacodynamic/efficacy model following oral administration of AZD8055
The PK profile of AZD8055 was determined following a single administration of 1.25 to 20 mg·kg À1 once daily in mice bearing U87-xenografts. The linear PK model described the observed PK well ( Figure 2A and Supporting Information Figure  S2 ). The total volume of distribution was 2.94 L·kg À1 , and the clearance was 2.89 L·h À1 ·kg À1 (Supporting Information   Table S1 ). After an initial rapid absorption phase, there was evidence of a slow second absorption phase resulting in an oral half-life longer than that following iv administration (data not shown ( Figure 2B , C) measured over time in tumour xenografts using immunoblotting were also modulated in a dose-dependent manner confirming previous studies (Chresta et al., 2010) .
The PK/PD model could describe the observed reduction in phosphorylated protein as a function of drug concentration. Interestingly, although the drug action was best described by an indirect effect, the turnover (de-phosphorylation) of the biomarkers was so rapid that it collapsed to a direct effect.
There was a direct relationship between plasma PK and biomarker inhibition (Supporting Information Figure S1 ), and the model fitted well the observed data for both biomarkers (Supporting Information Figures S3 and S4 ). Previously published in vitro data (Chresta et al., 2010) estimated IC 50 values of between 5 and 20 nM in U87-MG, A549 and MCF7 cell lines. The in vivo estimates are greater than this range in some cases; however, pS6 and pAkt are influenced by environmental conditions. The free fraction in mouse plasma of AZD8055 is 4% (Pike et al., 2013) suggesting greater total concentrations in mouse plasma would be required to achieve free concentrations comparable with the in vitro values. The mathematical model could describe the efficacy resulting from dosing AZD8055 orally in the U87-MG xenograft model ( Figure 2D and Supporting Information Figure  S5 ) without the need for the additional cell death effect. Thus, the duration and magnitude of biomarker inhibition were both important for efficacy.
Prediction of the antitumour activity across models based on pharmacodynamic profile and proliferation rate The next step was to test whether the predictive model built for U87-MG xenografts was applicable to other tumour xenografts. AZD8055 was tested for both its PD effect and tumour growth inhibition in 10 preclinical models from five different tumour types ( respectively). This disconnect between in vivo primary PD when continuously exposed to the compound and efficacy suggests that anti-tumour activity is driven by a second effect of cell death. This might explain the increased efficacy in some xenografted cell lines. Given that regression was observed in the Calu-3 model, the second drug effect of cell death was incorporated into the model that becomes important when the biomarker model predicts profound inhibition of the target. This was then tested against the experimental data ( Figure 3 ). In particular, the parameter estimates (Table 1) show that a significant modelled cell death effect (E max ) is required for the Calu3 xenografts to explain the higher efficacy compared with the A549 model. The percentage of cells positive for Ki67 in control tumours correlated positively with the modelled control growth rate ( Table 1) , demonstrating that modelled growth rate inferred by the modelled passage of cells through the cell cycle does correspond to the measured proliferating compartment. Overall, these data suggest that based on the overall modulation of the biomarkers over time, it is possible to predict the extent of the tumour growth inhibition in preclinical models with different sensitivity to AZD8055: reduction of proliferation predicted by biomarker reduction and a modelled cell death effect is predicted for biomarker inhibition >90%.
The antitumour efficacy of AZD8055 is only partly driven by high Cmax
Previous work from Solit et al. (2005) highlighted the potential benefit of high intermittent exposure to maximize the antitumour effect. This concept is ideally suited for compounds with short half-life like AZD8055, and a recent report from Rodrik-Outmezguine et al. (2011) concluded that duration of biomarkers was an important determinant of efficacy, something that would not occur after intermittent dosing. In order to test the contribution of a high Cmax to the antitumour effect, AZD8055 was administered i.p. in animals bearing U87-MG xenografts to generate a PK profile with a shorter half-life than that of oral dosing. It was hypothesized that this would result in a reduced duration of biomarker modulation compared with oral dosing. A dose of 20 mg·kg À1 i.p. (Figure 4A ) achieved a Cmax of higher than after administration of 20 mg·kg À1 by oral gavage. However, the clearance was more rapid after i.p. dosing resulting in reduced duration of exposure. Phospho-Akt decreased rapidly after i. p. administration to 9.5% of basal level after 30 min but recovered to baseline levels by 16 h ( Figure 4B ). The antitumour effect of AZD8055 in U87 xenografts was lower after administration of 20 mg·kg À1 AZD8055 i.p. (TGI = 65%) compared with 20 mg·kg À1 oral (TGI = 85%), confirming that the duration of biomarker modulation was an important component driving the antitumour effect. Indeed, the model ( Figure 4C ) could account for the differences in efficacy observed after oral and i.p. administration.
High-dose intermittent administration of AZD8055 alters the PK/PD/efficacy relationship
To establish whether prolonged high dose of AZD8055 was necessary to maximize the antitumour effect, AZD8055 was AZD8055. However, the PK profile was altered after oral dosing with prolonged high concentrations of AZD8055 observed up to 24 h after drug administration. This was even more apparent following administration of 80 mg·kg
À1
AZD8055 orally with a Cmax of 20 μM and plasma concentrations greater than 1 μM observed 48 h after administration ( Figure 4A ). This change in PK profile was associated with a profound change in biomarker profile ( Figure 4B AZD8055 once daily induced a rapid reduction in tumour volume ( Figure 4C ), and this antitumour effect was maintained for the duration of treatment (TGI = 107%). The administration of AZD8055 at a dose of 80 mg·kg À1 once weekly resulted in a superior anti-tumour activity compared with the i.p. and low oral doses, with regression being apparent early after the start of the treatment. However, tumour growth resumed during the drug holiday. Interestingly, overall, the 20 mg·kg À1 p.o. daily schedule resulted in comparable tumour growth inhibition to that of the 80 mg·kg À1 once weekly.
The modelling would suggest that the profound and prolonged pathway inhibition induces sufficient cell death that the tumour cannot recover in the washout period. Prolonged inhibition of proliferation would also be an important factor. These observations are accounted for in the model ( Figure 4C) , with both i.p. and high-dose oral treatment inducing cell death initially, but only the continued oral dose maintaining anti-tumour effect through the modelled anti-proliferation. This suggests that a once weekly high-dose administration of the compound has comparable benefit with a continuous dosing schedule at a lower concentration. However, the exposure to the compound are high concentrations maintained for 48 h, with the flat PK profile looking similar to that achieved with a continuous infusion ( Figure 4A ). All PD and tumour model parameters are reported in Supporting Information Table S2 .
Discussion
The current PK/PD/efficacy model links for the first time temporal biomarker modulation and reduction in tumour growth across a range of preclinical models with different sensitivity to the mTOR kinase inhibitor AZD8055. The model retains its predictive power when different routes and schedules of administration of AZD8055 are used.
PK/PD/efficacy models are highly dependent on the preclinical models used to build them. Engineered preclinical models or very sensitive models may overestimate the antitumour effect achievable in the clinic and may not be representative of the patient population treated with the agent. In this study, a PTEN-negative U87-MG glioblastoma xenograft was used to build the PK/PD/efficacy model. Mutations in PTEN are observed in~30% of glioblastoma tumours (Brennan et al., 2013) . PTEN loss has been shown to activate the PI3K pathway and to be associated with shorter survival in patients with glioblastoma (Yao et al., 2012) . However, in spite of the potential relevance of the U87-MG xenograft model, it has an extremely rapid growth rate and may be an outlier, so additional non-engineered xenograft models were also used to validate the initial PK/PD/efficacy model. The PK/PD/efficacy model described with the PI3K inhibitor GDC-0980 by Salphati et al. (2012) used an engineered xenograft model overexpressing human Her2 in an oestrogendependent breast cancer model MCF7. The predicted human daily dose to be associated with significant antitumour effect in the engineered model was 55 mg GDC-0980. Phase 1 study reported antitumour activity in three patients with mesothelioma at doses lower than 50 mg (Wagner et al., 2011) , so it is possible that a PK/PD/efficacy model built with mesothelioma xenografts may have predicted a different efficacious dose than the engineered model. PK/PD/efficacy models are often based on an exponential growth of the tumour xenografts, which may be accurate for fast growing xenograft models but may not reflect slow growing tumours in patients. In this study, a modified descriptive model of tumour growth rate as described by Simeoni et al. (2004) was used, and a relationship between Ki67 and growth rate estimated by the model was confirmed in control animals (Table 1) . Ki67 has been used as an early indicator of tumour Pharmacokinetics/pharmacodynamics modelling of AZD8055 BJP response to the mTOR inhibitor everolimus in breast cancer using paired tumour biopsies pre-and post-treatment (Baselga et al., 2009 ), so it may be possible to incorporate this biomarker in a predictive model of response in patients.
The mathematical modelling developed in the current study links biomarker modulation and reduction in tumour growth over time. This contrasts with previous PK/PD/efficacy studies linking a target concentration or biomarker threshold to be maintained chronically in order to drive antitumour efficacy. For example, Kogame et al. (2013) established a PK/PD/efficacy model for the Smo inhibitor TAK-441 in the PAN-04 xenograft model using biomarker assessment in tumour and skin and concluded that >83% reduction in Gli1 mRNA in the tumour was required for tumour stasis. Similarly, tumour stasis was achieved with the PI3K inhibitor GDC-0941 in MCF7.1 xenografts when plasma concentrations of~0.3 uM were maintained continuously (Salphati et al., 2010) . This type of approach is limited when intermittent dosing is proposed, so the current study evaluated the ability of the PK/PD/efficacy model to predict antitumour efficacy when altering different routes or schedules of administration. Delivering high concentrations of AZD8055 for a short duration, by i.p. dosing, did modulate the biomarkers transiently and did not produce a significant antitumour effect while prolonged high concentrations of AZD8055 maximizing biomarker modulation over time delivered the best antitumour effect. This supported the hypothesis that overall modulation of biomarkers over time was the main driver for efficacy. It also supported the concept first developed by Solit et al. (2005) with gefitinib that profound inhibition of a signalling pathway can switch the biological effect from growth inhibition to cell death by abolishing feedback loops. Importantly, the PK/PD/efficacy model still robustly predicted the antitumour effect observed even with an intermittent dosing schedule. A preclinical PK-efficacy model using the mTOR inhibitor MLN0128 used a tumour xenograft in conjunction with the clinical PK parameters to simulate tumour volume-time curves for various MLN0128 doses/schedules was recently reported (Patel et al., 2013) . It will be interesting to see whether additional parameters related to adverse events can be embedded in the future models, especially if intermittent dosing is driven by the mitigation of adverse events. The work reported here supports the possibility of two alternative schedules for dual mTOR inhibitors: continuous dosing to ensure continuous target coverage or an alternative high-dose intermittent schedule that would have to achieve complete target inhibition, at least around PK Cmax, to be as effective. Such regimens have been investigated for the dual mTOR kinase inhibitor AZD2014.
Overall, the findings from this study and the previously cited works indicate the potential predictive value of pharmacodynamically led efficacy analysis that could result in the reduction of the number of xenograft experiments required to guide dosing of previously untested compounds in efficacy studies. 
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